PT - JOURNAL ARTICLE AU - Marta Fernandez-Fuertes AU - Anaïs Corma-Gomez AU - Eva Torres AU - Elena Rodriguez-Pineda AU - Ana Fuentes-Lopez AU - Pilar Rincon AU - Nieves Fernanddez AU - Federico Garcia AU - Samuel Bernal AU - Luis M Real AU - Juan Macias AU - Juan A Pineda TI - Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain AID - 10.1101/2021.03.20.21253397 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.20.21253397 4099 - http://medrxiv.org/content/early/2021/03/24/2021.03.20.21253397.short 4100 - http://medrxiv.org/content/early/2021/03/24/2021.03.20.21253397.full AB - Background Whether people living with HIV (PLWH) are at greater risk of acquiring SARS-CoV-2 infection is currently unknown. Prospective serologic studies may allow seroincidence analyses, where all infections are accurately identified. Because of this, we evaluated the incidence of and associated factors with SARS-CoV-2 infection in PLWH in Southern Spain.Methods This was a prospective cohort study including PLWH from a University Hospital in Southern Spain. Patients were enrolled if 1) they had attended as outpatients our Unit from August 1st, 2019 to February 8th, 2020; 2) had two subsequent evaluations from February 9th, 2020 to February 15th, 2021. Serum antibodies against SARS-CoV-2 were determined in baseline and intra-pandemic samples.Results 710 PLWH were included in the study. Of them, 46 [6.5%, 95% confidence interval (95% CI): 4.8%-8.5%] patients developed SARS-CoV-2 infection. Between May 18th and November 29th, 2020, the rate of seroconversion was 5.3% (95% CI: 3.1%-9%) for the general population in the area of Seville and 2.3% (95% CI: 1.3%-3.6%) for PLWH in this study (p=0.001). After multivariate analysis, adjusted by age and sex, active tobacco smoking was the only factor independently associated with lower risk of SARS-Cov-2 infection (Incidence rate ratio 0.35, 95% CI: 0.18-0.68, p=0.002).Conclusions The incidence of SARS-CoV-2 infection among PLWH in Southern Spain during the ongoing pandemic was lower than that reported for the general population in the same area. Tobacco smoking was the only factor independently associated with a lower risk of incident SARS-CoV-2 infection.Summary The incidence of SARS-CoV-2 infection among people living with HIV is lower than that of general population in Southern Spain. Active tobacco smoking could be associated with a lower risk of developing COVID-19.Competing Interest StatementJM has been an investigator in clinical trials supported by Bristol-Myers Squibb, Gilead and Merck Sharp & Dome. He has received lectures fees from Gilead, Bristol-Myers Squibb, and Merck Sharp & Dome, and consulting fees from Bristol Myers-Squibb, Gilead, and Merck Sharp & Dome. JAP reports having received consulting fees from Bristol-Myers Squibb, Abbvie, ViiV Healthcare, Gilead, Merck Sharp & Dome, and Janssen Cilag. He has received research support from Bristol-Myers Squibb, ViiV Healthcare, Abbvie, Merck Sharp & Dome, Janssen Cilag and Gilead and has received lecture fees from Abbvie, Bristol-Myers Squibb, ViiV Healthcare, Merck Sharp & Dome, Abbvie, Janssen Cilag, and Gilead. FG reports having received consulting fees from Abbvie, ViiV Healthcare, Gilead, Merck Sharp & Dome, Roche, Hologic & Qiagen. He has received research support from ViiV Healthcare, Abbvie, and Merck Sharp & Dome, and has received lecture fees from Abbvie, ViiV Healthcare, Merck Sharp & Dome, Gilead, Roche, Hologic, Werfen and Intercept. The remaining authors report no conflict of interest. ACG has received lecture fees from Gilead, Merck Sharp & Dome and Abbvie.Funding StatementThis work was supported in part by the Instituto de Salud Carlos III (Project PI16/01443), integrated in the national I+D+i 2013-2016 and co-funded by the European Union (ERDF/ESF, Investing in your future), by the Spanish Network for AIDS investigation (RIS) (www.red.es/redes/inicio) (RD16/0025/0010, RD16/0025/0040), as a part of the Nacional I+ D+I, ISCIII Subdireccion General de Evaluacion and the European Fund for Development of Regions (FEDER). JAP has received a research extension grant from the Programa de Intensificacion de la Actividad de Investigacion del Servicio Nacional de Salud Carlos III (I3SNS). FG has received a research extension grant from the Programa de Intensificacion de la Actividad de Investigacion del Servicio Andaluz de Salud. ACG has received a Rio Hortega grant from the Instituto de Salud Carlos III (grant number CM19/00251).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was designed and conducted following the Helsinki declaration. The Ethics committee of the Hospital Universitario Virgen de Valme approved the study. All patients gave written informed consent to be entered in the cohort.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no other data